Claims for Patent: 6,641,834

Summary for Patent: 6,641,834

Title:	Compositions containing alpha-2-adrenergic agonist components
Abstract:	Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
Inventor(s):	Olejnik; Orest (Coto de Coza, CA), Kerslake; Edward D. S. (Charlestown, MA)
Assignee:	Allergan Sales, Inc. (Irvine, CA)
Application Number:	10/236,566
Patent Claims:	1. A therapeutically effective aqueous ophthalmic composition comprising: up to about 0.15% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline tartrate, the composition having a pH of about 7.0 or greater, and the 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline tartrate being soluble in the composition at about 21.degree. C. 2. The composition of claim 1 which includes up to 0.15% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline tartrate. 3. The composition of claim 1 which includes about 0.15% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline tartrate. 4. The composition of claim 1 which includes 0.15% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino)quinoxaline tartrate. 5. The composition of claim 1 having a pH of 7.0 or greater. 6. The composition of claim 1 which further comprises a preservative selected from the group consisting of an oxy-chloro component and a quaternary ammonium compound in an amount effective to at least assist in preserving the composition. 7. The composition of claim 6 wherein the oxy-chloro component comprises a chlorite component. 8. The composition of claim 1 which is substantially free of anionic cellulosic derivatives. 9. The composition of claim 1 which is substantially free of carboxymethyl cellulose. 10. A therapeutically effective aqueous ophthalmic composition comprising: up to about 0.15% (w/v) of a component selected from the group consisting of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, salts of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, esters of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline and mixtures thereof, the composition having a pH of about 7.0 or greater, and the component being soluble in the composition at about 21.degree. C. 11. The composition of claim 10 which includes up to 0.15% (w/v) of the component. 12. The composition of claim 10 which includes about 0.15% (w/v) of the component. 13. The composition of claim 10 which includes 0.15% (w/v) of the component. 14. The composition of claim 10 having a pH of 7.0 or greater. 15. The composition of claim 10, which further comprises an oxy-chloro component in an amount effective to at least assist in preserving the composition. 16. The composition of claim 15 wherein the oxy-chloro component comprises a chlorite component. 17. The composition of claim 10 which is substantially free of anionic cellulosic derivatives. 18. The composition of claim 10 which is substantially free of carboxymethyl cellulose. 19. The composition of claim 6 in which the preservative comprises benzalkonium chloride. 20. The composition of claim 10 which further comprises a preservative selected from the group consisting of an oxy-chloro component and a quaternary ammonium compound in an amount effective to at least assist in preserving the composition. 21. The composition of claim 20 in which the preservative comprises benzalkonium chloride. 22. The composition of claim 20 in, which the preservative comprises a oxy-chloro component.